

MATERIALS LICENSE

Amendment No. 08

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Campbell County Memorial Hospital</p> <p>2. 501 South Burma Gillette, Wyoming 82716</p>	<p>In accordance with letter dated September 24, 1985</p> <p>3. License number 49-18030-01 is amended in its entirety to read as follows:</p> <p>4. Expiration date October 31, 1988</p> <p>5. Docket or Reference No. 030-14365</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35</p> <p>B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35</p> <p>C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35</p> <p>D. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35</p>	<p>7. Chemical and/or physical form</p> <p>A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35</p> <p>B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35</p> <p>C. Any radiopharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35</p> <p>D. Any radiopharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35</p> <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As necessary for uses authorized in Subitem 9.A.</p> <p>B. 2 curies of each byproduct material authorized in Subitem 6.B.</p> <p>C. As necessary for uses authorized in Subitem 9.C.</p> <p>D. As necessary for uses authorized in Subitem 9.D.</p>

8602060198 851209
REG4 LIC30
49-18030-01 PDR

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number
49-18030-01

Docket or Reference number
030-14365

Amendment No. 08

E. Any byproduct material
listed in Section
31.11(a) of 10 CFR 31

E. Any

E. 3 millicuries of
each byproduct
material author-
ized in Subitem
6.E.

F. Xenon-133

F. Gas or gas in solution
that is the subject of
an active (i.e., not
withdrawn or terminated)
"New Drug Application"
(NDA) approved by FDA or
an active (i.e., not
withdrawn, terminated or
on "clinical hold")
"Notice of Claimed
Investigational Exemption
for a New Drug" (IND) that
has been accepted by FDA

F. 1 curie

9. Authorized use

- A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- D. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- E. In vitro studies.
- F. Blood flow or pulmonary function studies.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number
49-18030-01

Docket or Reference number
030-14365

Amendment No. 08

CONDITIONS

10. Licensed material shall be used only at Campbell County Memorial Hospital, 501 South Burma, Gillette, Wyoming.
11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."
12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Max G. Walter, M.D.

Groups I, II, III, IV, and V
Xenon-133
In vitro studies

James R. LaManna, M.D.

Groups I, II, and III
Xenon-133
In vitro studies

Seymour J. Stifel, M.D.

Groups I, II, and III
In vitro studies

Arthur W. Fayen, M.D.

In vitro studies

13. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.
14. For a period not to exceed 60 days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:
 - A. Has the prior written permission of the hospital's administrator and its Radiation Safety Committee, and
 - B. Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and

MATERIALS LICENSE
SUPPLEMENTARY SHEETLicense number
49-18030-01Docket or Reference number
030-14365

Amendment No. 08

14. (continued)

- C. Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

The licensee shall maintain for inspection by the Commission, copies of the written permission specified in Subitem A above and of the license(s) specified in Subitems B and C above. These records shall be maintained for 5 years from the time the licensee grants its permission under Subitem A above.

15. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:
- A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of 10 half-lives.
 - B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.
 - C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.
16. Patients containing iodine-131 for the treatment of thyroid carcinoma (or patients containing therapeutic quantities of gold-198) shall remain hospitalized until the residual activity is 30 millicuries or less.
17. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in:
- A. Application dated June 8, 1983
 - B. Letter dated September 29, 1983
 - C. Letter received November 15, 1983
 - D. Letter dated September 24, 1985

The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date DEC 9 1985Original Signed By
By C. L. CainNuclear Materials Safety Section
Region IV
Arlington, Texas 76011

Official Record Copy

11 MC48